Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome

NCT ID: NCT04383678

Last Updated: 2021-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

132 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate outcomes and predictors of outcome after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory syndrome (ARDS) in COVID-19 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Extracorporeal Membrane Oxygenation Complication Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 positive patients

Extracorporeal membrane oxygenation

Intervention Type DEVICE

Veno-venous or veno-arterial extracorporeal oxygenation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extracorporeal membrane oxygenation

Veno-venous or veno-arterial extracorporeal oxygenation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PCR-confirmed or suspected COVID-19 infection with ARDS who require any ECMO therapy

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helsinki University Central Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fausto Biancari

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fausto Biancari, Professor

Role: PRINCIPAL_INVESTIGATOR

Helsinki University Central Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helsinki University Hospital

Helsinki, , Finland

Site Status

University Hospital Jean Minjoz

Besançon, , France

Site Status

Nancy University Hospital

Nancy, , France

Site Status

Henri Mondon Unoversity Hospital

Paris, , France

Site Status

Robert Debré University Hospital

Reims, , France

Site Status

Hamburg University Heart Center

Hamburg, , Germany

Site Status

Münster University Hospital

Münster, , Germany

Site Status

S. Orsola Hospital

Bologna, , Italy

Site Status

Lecco Hospital

Lecco, , Italy

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

University Hospitals of Leicester

Leicester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland France Germany Italy Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Biancari F, Mariscalco G, Dalen M, Settembre N, Welp H, Perrotti A, Wiebe K, Leo E, Loforte A, Chocron S, Pacini D, Juvonen T, Broman LM, Perna DD, Yusuff H, Harvey C, Mongardon N, Maureira JP, Levy B, Falk L, Ruggieri VG, Zipfel S, Folliguet T, Fiore A. Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19. J Cardiothorac Vasc Anesth. 2021 Jul;35(7):1999-2006. doi: 10.1053/j.jvca.2021.01.027. Epub 2021 Jan 19.

Reference Type DERIVED
PMID: 33573928 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID-19 ECMO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.